Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 29, 2026

Qualcomm Is Down 37% From Its High and Reports Wednesday. Is the Stock a Buy?

View original at nasdaq.com
Qualcomm Is Down 37% From Its High and Reports Wednesday. Is the Stock a Buy? Key Points Qualcomm reports fiscal third-quarter results after the market closes on Wednesday, July 29…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The author would rather wait for more information before buying Qualcomm stock, even at the risk of missing a rebound.

    60% confidence

  • The consensus analyst rating on Qualcomm is hold, with an average price target of $221.23, about 36% above the current price of $162.88.

    60% confidence

  • Qualcomm expects handset revenue from Chinese customers to bottom in the fiscal Q3 quarter and return to sequential growth in the following quarter.

    60% confidence

  • A custom silicon engagement with a leading hyperscaler remains on track for initial shipments later this calendar year.

    60% confidence

  • Qualcomm delivered results in line with guidance, reflecting solid execution navigating a challenging memory environment.

    60% confidence

Data points we hold from this source

Qualcomm Incorporated · stock price162.88 USD
Qualcomm Incorporated · market share221.23 USD
Qualcomm Incorporated · cash3.7 USD
Qualcomm Incorporated · margin72 percent
Qualcomm Incorporated · eps2.65 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com